サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1375842

遺伝子治療の世界市場：タイプ別、ベクター別、治療領域別、デリバリー方法別、地域別 - 予測（～2028年）

Gene Therapy Market by Type, Vector (Viral, Non-viral ), Therapeutic Area, Delivery Method, RoA & Region - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 276 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
遺伝子治療の世界市場：タイプ別、ベクター別、治療領域別、デリバリー方法別、地域別 - 予測（～2028年）
出版日: 2023年10月30日
発行: MarketsandMarkets
ページ情報: 英文 276 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

レポートの概要

調査範囲
調査対象年 2023年～2028年
基準年 2022年
予測期間 2023年～2028年
検討単位 10億米ドル
セグメント タイプ、ベクター、治療領域、デリバリー方法、投与経路
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ

世界の遺伝子治療の市場規模は、2023年に90億米ドル、2028年までに239億米ドルに達し、予測期間にCAGRで21.4%の成長が見込まれています。

市場の主な成長促進要因は、ゲノム研究に関連する取り組みの増加、遺伝子治療製品に対する規制当局の承認の増加などです。さらに、細胞治療と遺伝子治療に対する需要の高まりは、この市場の機会分野です。

「治療領域別では、がん領域が市場で第2位のシェアを占めます」

2022年、がんに対する標的治療（遺伝子治療を含む）に対する需要の高まりや、がん有病率の増加などの要因により、がん領域がもっとも高い成長率をとなりました。

「デリバリー方法別では、in vivoセグメントが市場で最大のシェアを占めました」

2022年、in vivoセグメントが市場で最大のシェアを占めました。この市場セグメントの成長は、多くのin vivo遺伝子治療製品が市場で入手可能であることや、このデリバリー方法の研究開発に対する注目によるものと考えられます。

「北米：市場の最大のシェア」

北米が市場で最大のシェアを占めています。北米の大きなシェアは、遺伝子治療を提供する医療環境における先進技術を利用したインフラの存在や、先進の治療薬へのアクセスのしやすさなどの要因によるものと考えられます。また、同地域には確立された医療システムがあり、これが市場成長をさらに後押ししています。また同市場における主要企業のプレゼンスも重大な要因です。企業の例として、Novartis AG（スイス）、Biogen Inc.（米国）、Gilead Sciences, Inc.（米国）、Bristol-Myers Squibb（米国）、Alnylam Pharmaceuticals, Inc.（米国）、Sarepta Therapeutics, Inc.（米国）などが挙げられます。

「欧州：市場でもっとも急成長している地域」

欧州市場は、予測期間にもっとも高いCAGRで成長する見込みです。これは、遺伝子治療の進歩に向けた取り組みの高まりや、慢性疾患の有病率の増加、先進の標的治療の開発に政府機関が提供する支援などの要因によるものです。

当レポートでは、世界の遺伝子治療市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 遺伝子治療市場の概要
  • 北米の遺伝子治療市場、治療領域別、国別（2022年）
  • 遺伝子治療市場：ベクター別（2022年）
  • 遺伝子治療市場：地理的成長機会

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • ポーターのファイブフォース分析
  • 技術分析
  • バリューチェーン分析
  • エコシステム分析
  • 特許分析
  • パイプライン分析
  • サプライチェーン分析
  • 規制情勢
    • 規制分析
    • 規制機関、政府機関、その他の組織：地域別
  • 価格分析
  • 顧客のビジネスに影響を与える動向/混乱
  • 主な会議とイベント
  • 主なステークホルダーと購入基準

第6章 遺伝子治療市場：タイプ別

  • イントロダクション
  • 遺伝子サイレンシング
  • 細胞置換
  • 遺伝子増強
  • その他の治療

第7章 遺伝子治療市場：ベクター別

  • イントロダクション
  • ウイルスベクター
    • レトロウイルスベクター
    • アデノ随伴ウイルスベクター
    • その他のウイルスベクター
  • 非ウイルスベクター
    • オリゴヌクレオチド
    • その他の非ウイルスベクター

第8章 遺伝子治療市場：治療領域別

  • イントロダクション
  • 神経
  • 腫瘍
  • 肝臓
  • その他の治療領域

第9章 遺伝子治療市場：デリバリー方法別

  • イントロダクション
  • in vivo
  • ex vivo

第10章 遺伝子治療市場：投与経路別

  • イントロダクション
  • 静脈
  • その他の投与経路

第11章 遺伝子治療市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • 北米の不況の影響
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
    • 欧州の不況の影響
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
    • アジア太平洋の不況の影響
  • ラテンアメリカ
    • ブラジル
    • その他のラテンアメリカ
    • ラテンアメリカの不況の影響
  • 中東
  • アフリカ

第12章 競合情勢

  • 主要企業の戦略
  • 市場シェア分析
  • 収益分析
  • 企業の評価マトリクス
  • スタートアップ/中小企業の評価マトリクス
  • 競合シナリオと動向

第13章 企業プロファイル

  • 主要企業
    • NOVARTIS AG
    • BIOGEN INC.
    • GILEAD SCIENCES, INC.
    • BRISTOL-MYERS SQUIBB
    • ALNYLAM PHARMACEUTICALS, INC.
    • SAREPTA THERAPEUTICS, INC.
    • AMGEN, INC.
    • ORCHARD THERAPEUTICS PLC
    • F. HOFFMANN-LA ROCHE AG
    • JAZZ PHARMACEUTICALS PLC
    • UNIQURE N.V.
    • JOHNSON & JOHNSON
    • BLUEBIRD BIO, INC.
    • BIOMARIN PHARMACEUTICAL INC.
    • KRYSTAL BIOTECH, INC.
    • SHANGHAI SUNWAY BIOTECH CO. LTD.
    • SIBIONO GENETECH CO. LTD.
  • その他の企業
    • FERRING B.V.
    • VERTEX PHARMACEUTICALS INCORPORATED
    • PFIZER, INC.
    • SANGAMO THERAPEUTICS, INC.
    • REGENXBIO
    • ULTRAGENYX PHARMACEUTICAL INC.
    • MEIRAGTX HOLDINGS PLC
    • ANGES, INC.

第14章 付録

目次
Product Code: BT 7506

Report Description

Scope of the Report
Years Considered for the Study2023-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
Segmentstype, vector, therapeutic area, delivery method, route of administration
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

The gene therapy market is expected to reach USD 23.9 billion by 2028 from USD 9.0 billion in 2023, at a CAGR of 21.4% during the forecast period. The key factors driving the growth of the gene therapy market include increasing initiatives related to genomic research, and increasing number of regulatory approvals for gene therapy products. Moreover, growing demand for cell and gene therapies is an opportunity area for this market.

The gene therapy market has been segmented based on type, vector, therapeutic area, delivery method, route of administration and region.

"By therapeutic area, oncology segment accounted for the second largest share of the gene therapy market"

Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas.. In 2022, oncology accounted for the highest growth rate owing to factors such as The rising demand for targeted therapies (including gene therapy) against cancer, increasing cancer prevalence are the major factors driving the growth of this segment.

"By delivery method, the in vivo segment accounted for the largest share in the gene therapy market"

Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo. In 2022, the in vivo segment accounted for a largest share of the gene therapy market. Growth in this market segment can be attributed to availability of many in vivo gene therapy products commercially and focus of research and development on this delivery method.

"North America: the largest share of the gene therapy market"

North America accounted for the largest share of the gene therapy market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering gene therapies, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, presence of some of the key players in the market is another key factor. Some examples of these players include Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others.

"Europe: The fastest-growing region in the gene therapy market."

The Europe gene therapy market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of gene therapies, increasing prevalence of chronic diseases and support offered by the government organizations for developing advanced targeted therapies.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
  • By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%

Prominent Players

  • Novartis AG (Switzerland)
  • Biogen Inc. (US)
  • Gilead Sciences, Inc. (US)
  • Bristol-Myers Squibb (US)
  • Alnylam Pharmaceuticals, Inc. (US)
  • Sarepta Therapeutics, Inc. (US)
  • Amgen, Inc. (US)
  • Orchard Therapeutics Plc (UK)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Jazz Pharmaceuticals Plc (Ireland)
  • uniQure N.V. (Netherlands)
  • Johnson & Johnson (US)
  • Bluebird Bio, Inc. (US)
  • BioMarin Pharmaceutical Inc. (US)
  • Krystal Biotech, Inc. (US)
  • Shanghai Sunway Biotech Co. Ltd. (China)
  • SIBIONO GeneTech Co. Ltd. (China)
  • Ferring B.V. (Switzerland)
  • Vertex Pharmaceuticals Incorporated (US)
  • Pfizer, Inc. (US)
  • Sangamo Therapeutics, Inc. (US)
  • REGENXBIO (US)
  • Ultragenyx Pharmaceutical Inc. (US)
  • MeiraGTx Holdings Plc (US)
  • AnGes, Inc. (Japan)

Research Coverage:

This report provides a detailed picture of the gene therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers"

  • Analysis of key drivers (growth in regulatory approvals for gene therapy products), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with supply chain) influencing the growth of the gene therapy market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the gene therapy market.
  • Market Development: Comprehensive information about lucrative markets- the report analyses the gene therapy market across varied regions.
  • Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the gene therapy market.
  • Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Amgen, Inc. (US), Orchard Therapeutics Plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), among others in the gene therapy market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 GENE THERAPY MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 GENE THERAPY MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION OF GENE THERAPY MARKET
    • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 5 MARKET SIZE ESTIMATION FOR GENE THERAPY MARKET: REVENUE SHARE ANALYSIS
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH FORECAST
    • FIGURE 8 GENE THERAPY MARKET: CAGR PROJECTIONS
    • FIGURE 9 GENE THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 11 GENE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 GENE THERAPY MARKET, BY DELIVERY METHOD, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET

4 PREMIUM INSIGHTS

  • 4.1 GENE THERAPY MARKET OVERVIEW
    • FIGURE 17 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH TO DRIVE GROWTH IN GENE THERAPY MARKET
  • 4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA & COUNTRY (2022)
    • FIGURE 18 NEUROLOGY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • 4.3 GENE THERAPY MARKET, BY VECTOR, 2022
    • FIGURE 19 VIRAL VECTORS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing regulatory approvals for gene therapy products
    • TABLE 2 LIST OF KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2021-2023
      • 5.2.1.2 Increasing investments in gene therapy research
      • 5.2.1.3 Growing technological advancements
    • TABLE 3 LIST OF ADVANCED PLATFORMS LAUNCHED IN GENE THERAPY MARKET, 2022-2023
      • 5.2.1.4 Rising prevalence of genetic disorders and cancer
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of gene therapy products
    • TABLE 4 COST OF GENE THERAPY PRODUCTS
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for cell & gene therapies
      • 5.2.3.2 Increasing focus on precision medicine
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complex manufacturing process
      • 5.2.4.2 Short shelf life and supply chain challenges
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 GENE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 THREAT OF SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF SUPPLIERS
    • 5.3.4 BARGAINING POWER OF BUYERS
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 TECHNOLOGY ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 22 GENE THERAPY MARKET: VALUE CHAIN
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 23 GENE THERAPY MARKET: ECOSYSTEM MAP
  • 5.7 PATENT ANALYSIS
    • FIGURE 24 PATENT APPLICATIONS FOR GENE THERAPY PRODUCTS, JANUARY 2012-SEPTEMBER 2023
    • TABLE 6 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS
  • 5.8 PIPELINE ANALYSIS
    • TABLE 7 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE
  • 5.9 SUPPLY CHAIN ANALYSIS
    • FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
    • TABLE 8 SUPPLY CHAIN ECOSYSTEM
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY ANALYSIS
    • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
    • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PRICING ANALYSIS
    • 5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
    • TABLE 13 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS
    • TABLE 14 AVERAGE SELLING PRICE OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.13 KEY CONFERENCES & EVENTS
    • TABLE 15 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023-2024)
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS
    • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GENE THERAPY PRODUCTS IN HOSPITALS AND CLINICS
    • 5.14.2 BUYING CRITERIA FOR GENE THERAPY MARKET
    • FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS

6 GENE THERAPY MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 16 GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2 GENE SILENCING
    • 6.2.1 HIGH FLEXIBILITY AND PRECISION OFFERED BY GENE SILENCING THERAPIES TO SUPPORT GROWTH
    • TABLE 17 GENE SILENCING THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 18 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 19 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 20 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 CELL REPLACEMENT
    • 6.3.1 LONG-TERM EFFECTS OF CELL REPLACEMENT THERAPY TO BOOST ADOPTION
    • TABLE 22 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 23 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 GENE AUGMENTATION
    • 6.4.1 GROWING USE OF GENE AUGMENTATION THERAPY AGAINST MONOGENIC DISORDERS TO FAVOR MARKET GROWTH
    • TABLE 27 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 OTHER THERAPIES

7 GENE THERAPY MARKET, BY VECTOR

  • 7.1 INTRODUCTION
    • TABLE 32 GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
  • 7.2 VIRAL VECTORS
    • TABLE 33 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 34 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.1 RETROVIRAL VECTORS
    • TABLE 39 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 40 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.1.1 Gamma retroviral vectors
        • 7.2.1.1.1 Availability of wide range of gamma-retroviral vectors to support market growth
    • TABLE 45 GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 LATIN AMERICA: GENE THERAPY MARKET FOR GAMMA RETROVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.1.2 Lentiviral vectors
        • 7.2.1.2.1 North America to dominate lentiviral vectors market
    • TABLE 50 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 LATIN AMERICA: GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.2 ADENO-ASSOCIATED VIRAL VECTORS
      • 7.2.2.1 Growing clinical pipeline of adeno-associated viral vectors to drive growth
    • TABLE 55 GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 EUROPE: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 LATIN AMERICA: GENE THERAPY MARKET FOR ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.3 OTHER VIRAL VECTORS
    • TABLE 60 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 NON-VIRAL VECTORS
    • TABLE 65 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 LATIN AMERICA: GENE THERAPY MARKET FOR N0N-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.1 OLIGONUCLEOTIDES
      • 7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market
    • TABLE 71 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 LATIN AMERICA: GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.2 OTHER NON-VIRAL VECTORS
    • TABLE 76 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 77 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY COUNTRY, 2021-2028 (USD MILLION)

8 GENE THERAPY MARKET, BY THERAPEUTIC AREA

  • 8.1 INTRODUCTION
    • TABLE 81 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
  • 8.2 NEUROLOGY
    • 8.2.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
    • TABLE 82 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 ONCOLOGY
    • 8.3.1 GROWING DEMAND FOR TARGETED THERAPIES AGAINST CANCERS TO DRIVE MARKET GROWTH
    • TABLE 87 PIPELINE PRODUCTS FOR ONCOLOGY APPLICATIONS
    • TABLE 88 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
    • TABLE 89 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 90 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 HEPATOLOGY
    • 8.4.1 GROWING R&D ACTIVITIES FOR LIVER CONDITIONS TO SUPPORT GROWTH
    • TABLE 94 GENE THERAPY MARKET FOR HEPATOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 95 NORTH AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 LATIN AMERICA: GENE THERAPY MARKET FOR HEPATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER THERAPEUTIC AREAS
    • TABLE 99 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 100 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 103 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

9 GENE THERAPY MARKET, BY DELIVERY METHOD

  • 9.1 INTRODUCTION
    • TABLE 104 GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
  • 9.2 IN VIVO
    • 9.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
    • TABLE 105 COMMERCIALIZED AND PIPELINE IN VIVO-BASED GENE THERAPY PRODUCTS
    • TABLE 106 IN VIVO GENE THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 107 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 108 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 110 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 EX VIVO
    • 9.3.1 GROWING FOCUS ON ONCOLOGY BY MARKET PLAYERS TO SUPPORT MARKET GROWTH
    • TABLE 111 COMMERCIALIZED AND PIPELINE EX VIVO-BASED GENE THERAPY PRODUCTS
    • TABLE 112 EX VIVO GENE THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 113 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 115 ASIA PACIFIC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

10 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION

  • 10.1 INTRODUCTION
    • TABLE 117 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • 10.2 INTRAVENOUS
    • 10.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
    • TABLE 118 GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 119 NORTH AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 120 EUROPE: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 LATIN AMERICA: GENE THERAPY MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 OTHER ROUTES OF ADMINISTRATION
    • TABLE 123 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 124 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 125 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 126 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)

11 GENE THERAPY MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 128 GENE THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
    • TABLE 129 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 132 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 133 NORTH AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 135 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 136 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 137 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Growing regulatory approvals and availability of advanced treatments to drive market growth
    • TABLE 138 US FDA APPROVALS FOR GENE THERAPY PRODUCTS
    • TABLE 139 US: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 140 US: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 141 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 142 US: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 143 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 145 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 146 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Growing gene therapy research initiatives to support growth
    • TABLE 147 CANADA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 148 CANADA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 149 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 150 CANADA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 153 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 154 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.2.3 NORTH AMERICA: RECESSION IMPACT
  • 11.3 EUROPE
    • FIGURE 29 EUROPE: GENE THERAPY MARKET SNAPSHOT
    • TABLE 155 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 156 EUROPE: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 157 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 158 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 161 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 162 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 163 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Growing collaborations in market to boost growth
    • TABLE 164 GERMANY: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 166 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 167 GERMANY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 169 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 170 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 171 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Strong government support to drive market growth
    • TABLE 172 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 173 UK: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 UK: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 175 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 176 UK: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 179 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 180 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Increasing initiatives in genomic research to drive market
    • TABLE 181 FRANCE: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 182 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 183 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 184 FRANCE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 185 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 187 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 188 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Initiatives for gene therapy development to drive growth
    • TABLE 189 ITALY: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 190 ITALY: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 191 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 ITALY: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 193 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 194 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 195 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 196 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Genomics initiatives and funding to support market growth
    • TABLE 197 SPAIN: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 198 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 199 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 200 SPAIN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 201 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 202 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 203 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 204 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 205 REST OF EUROPE: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 206 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 207 REST OF EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 208 REST OF EUROPE: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 209 REST OF EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 210 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 211 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 212 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.3.7 EUROPE: RECESSION IMPACT
  • 11.4 ASIA PACIFIC
    • TABLE 213 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 214 ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 215 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 216 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 217 ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 218 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 219 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 220 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 221 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 China to dominate gene therapy market in APAC during forecast period
    • TABLE 222 CHINA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 223 CHINA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 224 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 225 CHINA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 226 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 227 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 228 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 229 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Increasing initiatives supporting gene therapy adoption to propel market growth
    • TABLE 230 JAPAN: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 231 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 232 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 233 JAPAN: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 234 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 235 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 236 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 237 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Increasing burden of chronic diseases to drive market growth
    • TABLE 238 INDIA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 239 INDIA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 240 INDIA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 241 INDIA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 242 INDIA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 243 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 244 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 245 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 246 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 247 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 248 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 249 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 250 REST OF ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 251 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 252 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 253 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 11.5 LATIN AMERICA
    • TABLE 254 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 255 LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 256 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 257 LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 258 LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 259 LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 260 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 261 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 262 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.5.1 BRAZIL
      • 11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
    • TABLE 263 BRAZIL: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 264 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 265 BRAZIL: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 266 BRAZIL: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 267 BRAZIL: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 268 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 269 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 270 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.5.2 REST OF LATIN AMERICA
    • TABLE 271 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 272 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 273 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 274 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 275 REST OF LATIN AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 276 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 277 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 278 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.5.3 LATIN AMERICA: RECESSION IMPACT
  • 11.6 MIDDLE EAST
    • 11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
    • TABLE 279 MIDDLE EAST: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 280 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 281 MIDDLE EAST: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 282 MIDDLE EAST: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 283 MIDDLE EAST: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 284 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 285 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 286 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.6.2 MIDDLE EAST: RECESSION IMPACT
  • 11.7 AFRICA
    • 11.7.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS
    • TABLE 287 AFRICA: GENE THERAPY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 288 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2021-2028 (USD MILLION)
    • TABLE 289 AFRICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 290 AFRICA: GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 291 AFRICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 292 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 293 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2021-2028 (USD MILLION)
    • TABLE 294 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • 11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 KEY PLAYER STRATEGIES
    • FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET
  • 12.2 MARKET SHARE ANALYSIS
    • FIGURE 31 GENE THERAPY MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
    • TABLE 295 GENE THERAPY MARKET: DEGREE OF COMPETITION
  • 12.3 REVENUE ANALYSIS
    • FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES (2020-2022)
  • 12.4 COMPANY EVALUATION MATRIX
    • 12.4.1 STARS
    • 12.4.2 EMERGING LEADERS
    • 12.4.3 PERVASIVE PLAYERS
    • 12.4.4 PARTICIPANTS
    • FIGURE 33 COMPANY EVALUATION MATRIX, 2022
    • 12.4.5 COMPANY FOOTPRINT
      • 12.4.5.1 Company therapeutic area footprint
    • TABLE 296 THERAPEUTIC AREA FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET
      • 12.4.5.2 Company regional footprint
    • TABLE 297 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN GENE THERAPY MARKET
  • 12.5 START-UP/SME EVALUATION MATRIX
    • 12.5.1 PROGRESSIVE COMPANIES
    • 12.5.2 RESPONSIVE COMPANIES
    • 12.5.3 DYNAMIC COMPANIES
    • 12.5.4 STARTING BLOCKS
    • FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022
    • 12.5.5 COMPETITIVE BENCHMARKING
    • TABLE 298 GENE THERAPY MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 299 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • 12.6 COMPETITIVE SCENARIO AND TRENDS
    • 12.6.1 PRODUCT APPROVALS
    • TABLE 300 GENE THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2020-AUGUST 2023
    • 12.6.2 DEALS
    • TABLE 301 GENE THERAPY MARKET: DEALS, JANUARY 2020-AUGUST 2023
    • 12.6.3 OTHER DEVELOPMENTS
    • TABLE 302 GENE THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2020-AUGUST 2023

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 13.1.1 NOVARTIS AG
    • TABLE 303 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 35 NOVARTIS AG: COMPANY SNAPSHOT (2022)
    • TABLE 304 NOVARTIS AG: PRODUCT APPROVALS
    • TABLE 305 NOVARTIS AG: DEALS
    • TABLE 306 NOVARTIS AG: OTHER DEVELOPMENTS
    • 13.1.2 BIOGEN INC.
    • TABLE 307 BIOGEN INC.: COMPANY OVERVIEW
    • FIGURE 36 BIOGEN INC.: COMPANY SNAPSHOT (2022)
    • TABLE 308 BIOGEN INC.: DEALS
    • TABLE 309 BIOGEN INC.: OTHER DEVELOPMENTS
    • 13.1.3 GILEAD SCIENCES, INC.
    • TABLE 310 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
    • FIGURE 37 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 311 GILEAD SCIENCES, INC.: PRODUCT APPROVALS
    • TABLE 312 GILEAD SCIENCES, INC.: DEALS
    • TABLE 313 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS
    • 13.1.4 BRISTOL-MYERS SQUIBB
    • TABLE 314 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
    • FIGURE 38 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022)
    • TABLE 315 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS
    • TABLE 316 BRISTOL-MYERS SQUIBB: DEALS
    • 13.1.5 ALNYLAM PHARMACEUTICALS, INC.
    • TABLE 317 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 39 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 318 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS
    • TABLE 319 ALNYLAM PHARMACEUTICALS, INC.: DEALS
    • 13.1.6 SAREPTA THERAPEUTICS, INC.
    • TABLE 320 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
    • FIGURE 40 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)
    • TABLE 321 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS
    • TABLE 322 SAREPTA THERAPEUTICS, INC.: DEALS
    • TABLE 323 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS
    • 13.1.7 AMGEN, INC.
    • TABLE 324 AMGEN, INC.: COMPANY OVERVIEW
    • FIGURE 41 AMGEN, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 325 AMGEN, INC.: DEALS
    • TABLE 326 AMGEN, INC.: OTHER DEVELOPMENTS
    • 13.1.8 ORCHARD THERAPEUTICS PLC
    • TABLE 327 ORCHARD THERAPEUTICS PLC: COMPANY OVERVIEW
    • FIGURE 42 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT (2022)
    • TABLE 328 ORCHARD THERAPEUTICS PLC: PRODUCT APPROVALS
    • TABLE 329 ORCHARD THERAPEUTICS PLC: DEALS
    • 13.1.9 F. HOFFMANN-LA ROCHE AG
    • TABLE 330 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
    • FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)
    • 13.1.10 JAZZ PHARMACEUTICALS PLC
    • TABLE 331 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
    • FIGURE 44 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2022)
    • TABLE 332 JAZZ PHARMACEUTICALS PLC: DEALS
    • 13.1.11 UNIQURE N.V.
    • TABLE 333 UNIQURE N.V.: COMPANY OVERVIEW
    • FIGURE 45 UNIQURE N.V.: COMPANY SNAPSHOT (2022)
    • TABLE 334 UNIQURE N.V.: PRODUCT APPROVALS
    • TABLE 335 UNIQURE N.V.: DEALS
    • 13.1.12 JOHNSON & JOHNSON
    • TABLE 336 JOHNSON & JOHNSON: COMPANY OVERVIEW
    • FIGURE 46 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
    • TABLE 337 JOHNSON & JOHNSON: PRODUCT APPROVALS
    • TABLE 338 JOHNSON & JOHNSON: DEALS
    • 13.1.13 BLUEBIRD BIO, INC.
    • TABLE 339 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
    • FIGURE 47 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 340 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES & APPROVALS
    • 13.1.14 BIOMARIN PHARMACEUTICAL INC.
    • TABLE 341 BIOMARIN PHARMACEUTICAL INC.: COMPANY OVERVIEW
    • FIGURE 48 BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT (2022)
    • TABLE 342 BIOMARIN PHARMACEUTICAL INC.: DEALS
    • TABLE 343 BIOMARIN PHARMACEUTICAL INC.: PRODUCT APPROVALS
    • 13.1.15 KRYSTAL BIOTECH, INC.
    • TABLE 344 KRYSTAL BIOTECH, INC.: COMPANY OVERVIEW
    • TABLE 345 KRYSTAL BIOTECH, INC.: PRODUCT APPROVALS
    • TABLE 346 KRYSTAL BIOTECH, INC.: DEALS
    • TABLE 347 KRYSTAL BIOTECH, INC.: OTHER DEVELOPMENTS
    • 13.1.16 SHANGHAI SUNWAY BIOTECH CO. LTD.
    • TABLE 348 SHANGHAI SUNWAY BIOTECH CO. LTD.: COMPANY OVERVIEW
    • 13.1.17 SIBIONO GENETECH CO. LTD.
    • TABLE 349 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
  • 13.2 OTHER PLAYERS
    • 13.2.1 FERRING B.V.
    • 13.2.2 VERTEX PHARMACEUTICALS INCORPORATED
    • 13.2.3 PFIZER, INC.
    • 13.2.4 SANGAMO THERAPEUTICS, INC.
    • 13.2.5 REGENXBIO
    • 13.2.6 ULTRAGENYX PHARMACEUTICAL INC.
    • 13.2.7 MEIRAGTX HOLDINGS PLC
    • 13.2.8 ANGES, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS